86.95
-3.78 (-4.17%)
| Penutupan Terdahulu | 90.73 |
| Buka | 90.00 |
| Jumlah Dagangan | 792,874 |
| Purata Dagangan (3B) | 486,658 |
| Modal Pasaran | 4,213,805,568 |
| Harga / Jualan (P/S) | 14.00 |
| Harga / Buku (P/B) | 51.93 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 18 Feb 2025 - 24 Feb 2025 |
| Margin Keuntungan | -91.87% |
| Margin Operasi (TTM) | -44.13% |
| EPS Cair (TTM) | -6.58 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 81.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 207.00% |
| Nisbah Semasa (MRQ) | 2.44 |
| Aliran Tunai Operasi (OCF TTM) | -132.57 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -42.44 M |
| Pulangan Atas Aset (ROA TTM) | -26.44% |
| Pulangan Atas Ekuiti (ROE TTM) | -171.61% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Axsome Therapeutics, Inc. | Menurun | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | -0.5 |
| Purata | 0.25 |
|
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 16.68% |
| % Dimiliki oleh Institusi | 81.09% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Alethea Capital Management, Llc | 30 Sep 2024 | 738,503 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 180.00 (HC Wainwright & Co., 107.02%) | Beli |
| Median | 130.00 (49.51%) | |
| Rendah | 116.00 (Baird, 33.41%) | Beli |
| Purata | 135.60 (55.95%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 95.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 12 Dec 2024 | 121.00 (39.16%) | Beli | 94.37 |
| HC Wainwright & Co. | 27 Nov 2024 | 180.00 (107.02%) | Beli | 99.65 |
| 25 Nov 2024 | 180.00 (107.02%) | Beli | 97.50 | |
| Baird | 13 Nov 2024 | 116.00 (33.41%) | Beli | 97.83 |
| Needham | 13 Nov 2024 | 130.00 (49.51%) | Beli | 97.83 |
| 12 Nov 2024 | 130.00 (49.51%) | Beli | 99.49 | |
| RBC Capital | 04 Oct 2024 | 131.00 (50.66%) | Beli | 86.59 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Nov 2024 | Pengumuman | Axsome Therapeutics Presents Data from Its Leading Neuroscience Pipeline at NEI Congress 2024 |
| 29 Oct 2024 | Pengumuman | Axsome Therapeutics Presents Data from Multiple Programs Spanning Its Innovative Neuroscience Portfolio at Psych Congress 2024 |
| 15 Oct 2024 | Pengumuman | Axsome Therapeutics to Report Third Quarter 2024 Financial Results on November 12 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |